The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•18 June 2026•

1 min read

FDA Expands Approval for Merck’s Capvaxive Vaccine to Include Children

Key Facts

1The U.S. FDA approved a label expansion for Merck's Capvaxive vaccine to include children and teenagers at higher risk of pneumococcal disease.

2The vaccine targets Streptococcus pneumoniae in children with chronic health conditions.

In a move that strengthens the company's position in the competitive vaccine market, the U.S. FDA has approved a label expansion for Merck's Capvaxive vaccine to include children and teenagers. According to reports, this expansion targets younger populations at higher risk of Streptococcus pneumoniae infection, specifically those with underlying chronic health conditions. The decision aims to provide critical immunization to a broader and clinically vulnerable patient demographic.

This approval places Merck in direct competition with Pfizer, whose Prevnar 20 vaccine has long dominated the pediatric pneumococcal market. Per market data, Merck (MRK) shares closed at $115.49 on June 17, 2026, while financial reports for Pfizer indicate that its Prevnar franchise generates billions in annual revenue, highlighting the strategic importance of this market share expansion.

Investors should watch MRK price levels, which reached a high of $115.99 as of the June 17, 2026 close. Looking ahead, the market will monitor the upcoming Michigan Consumer Sentiment index in the U.S. for broader sector sentiment, alongside any further clinical recommendations from the CDC regarding the vaccine's implementation in pediatric schedules.